What question did this study set out to answer?

To review recent landmark clinical trial evidence, updated practice guidelines, and evolving therapeutic strategies across the spectrum of heart failure phenotypes.

December 1, 2021ESC Heart FailureOpen Access

A Year in Heart Failure: An Update of Recent Findings

View Full Paper

Ask AI

Bookmark

Why the study?

Major changes have occurred in recent years in heart failure management, warranting an update of recent findings and guideline recommendations.

Key Points

To review recent landmark clinical trial evidence, updated practice guidelines, and evolving therapeutic strategies across the spectrum of heart failure phenotypes.
Synthesized findings from recent randomized clinical trials, including the EMPEROR-Preserved and AFFIRM-AHF studies.
Evaluated the 2021 European Society of Cardiology guideline recommendations for heart failure with reduced and preserved ejection fraction.
Four drug classes (ACEi/ARNI, beta-blockers, MRAs, and SGLT2 inhibitors) consistently reduce mortality and hospitalizations in heart failure with reduced ejection fraction.
In the EMPEROR-Preserved trial, empagliflozin reduced cardiovascular death or heart failure hospitalization by 21% compared with placebo (HR 0.79, 95% CI 0.69 to 0.90, P < 0.001).
In the AFFIRM-AHF trial, ferric carboxymaltose achieved a 26% reduction in total heart failure hospitalizations versus placebo in acute heart failure patients with iron deficiency (P = 0.013).

Structured PICO

Population

Patients with heart failure, including HFrEF, HFpEF, and specific phenotypes (atrial fibrillation, valvular heart disease, cardiomyopathies, cardiac amyloidosis, and cancer-related HF)

Intervention

Recent advances in heart failure management including guideline-directed medical therapy (ACEi/ARNI, beta-blockers, MRA, SGLT2i), ferric carboxymaltose, vericiguat, and omecamtiv mecarbil

This review highlights major recent advances in heart failure management, including the establishment of foundational therapies for HFrEF and the breakthrough of empagliflozin for HFpEF.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports integration of foundational HFrEF therapies and empagliflozin in HFpEF; leaves open optimal implementation and comparative outcomes.

Cite This Study

Stretti et al. (2021) studied this question.

synapsesocial.com/papers/6a08aa3f280cd4e998e8d70d https://doi.org/10.1002/ehf2.13760

Topics

HFrEF treatment Heart failure HFpEF management Heart failure hospitalization SGLT2 inhibitors in heart failure

View Full Paper

Ask AI

Bookmark

Implication

Supports integration of foundational HFrEF therapies and empagliflozin in HFpEF; leaves open optimal implementation and comparative outcomes.

A Year in Heart Failure: An Update of Recent Findings

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

A Year in Heart Failure: An Update of Recent Findings

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider